Table 2.
Comparison of bone marrow cellularity, plasma cells percentage, and cytogenetics at diagnosis and ASCT1, between single and tandem ASCT groups.
| ≥VGPR/SINGLE ASCT | ≤PR/TANDEM ASCT | P-VALUE | |
|---|---|---|---|
| Bone marrow at diagnosis | |||
| Cellularity % | 64 (5–100) | 55 (40–100) | 0.65 |
| Plasma cells % | 40 (2.5–100) | 50 (2.5–90) | 0.94 |
|
| |||
| Bone marrow at ASCT1 | |||
| Cellularity % | 40 (10–82.5) | 47.5 (20–97.5) | 0.36 |
| Plasma cells % | 3 (0–70) | 7.5 (1.5–80) | 0.0047 |
|
| |||
| Cytogenetics at diagnosis, N* | |||
| High-risk** | 5 | 3 | 0.71 |
| Standard-risk | 16 | 11 | |
|
| |||
| Cytogenetics at ASCT1, N | |||
| High-risk | 7 | 3 | 0.76 |
| Standard-risk | 29 | 24 | |
Notes:
*
Cytogenetics ± FISH were available only in 35 patients.
**
High risk includes del 13/13q by cytogenetics only, complex chromosomal abnormalities, and hypodiploidy. Other known high-risk abnormalities were not detected in our patients.